Biotechnology Press Release
|08/28/2013 - 04:43||
Stem Cell Agency Awards More than $40 Million in New Research Grants
La Jolla, CA –Prostate cancer, heart and liver disease, autism, and HIV/AIDS are among the diseases targeted by the state’s stem cell agency, the California Institute for Regenerative Medicine (CIRM), in its latest round of funding.
|08/26/2013 - 08:29||
2013 Axel Hirsch Prize awarded to stem cell researcher in Ophthalmology
PRESS RELEASE 26 AUGUST 2013] Anders Kvanta, Chief Physician at the St. Erik Eye Hospital and Adjunct Professor of Ophthalmology at the Department of Clinical Neuroscience, Karolinska Institutet is awarded this year's Axel Hirsch Prize. He is given the award for research which lays the foundation for treating one of our most common retinal diseases.
|08/26/2013 - 04:45||
Novartis holds annual healthcare entrepreneur competition to generate insight into healthcare and innovation of tomorrow
Basel, August 26, 2013 - Novartis has invited 60 selected students from leading international universities in 21 countries to its headquarters in Switzerland for the International Biotechnology Leadership Camp (BioCamp). Over the course of three days, students will gain first-hand experience of starting a biotechnology company as well as developing and launching an innovative healthcare product. This year's BioCamp focuses on the Company's innovation efforts in new business approaches to the healthcare industry.
|08/25/2013 - 17:42||
Amgen and Onyx Pharmaceuticals Announce Early Termination of HSR Waiting Period for Amgen's Acquisition of Onyx
Thousand Oaks, CA and South San Francisco, CA. Sep.
|08/21/2013 - 08:26||
Research with the Moss Bioreactor
The Chair of Plant Biotechnology from the University of Freiburg, Germany, and the biopharmaceutical company greenovation Biotech GmbH in Heilbronn, Germany, have started a cooperation to enhance the yield of recombinant proteins from moss. The moss Physcomitrella patens can be grown in closed containers such as bioreactors with a volume of up to 500 litres. In these Moss Bioreactors complex proteins can be produced.
|08/21/2013 - 03:04||
US and UK scientists collaborate to design crops of the future
By 2015, more than 190 million tons of nitrogen will be needed to supply the world's food.
|08/20/2013 - 23:07||
PharmaCM CT 2.0 to Help Pharma Manage Multinational Registries
NEW YORK, August 20, 2013 – With the life sciences R&D industry undergoing a “major shift around modernization,” Deloitte Analytics LLC is releasing PharmaCM CT 2.0, a solution that gives pharmaceutical and biotech companies one system for managing the clinical trial application process in both the United States and Europe.
|08/19/2013 - 04:41||
Patient Advisory for Stem Cell Therapy and Medical Tourism
As stakeholders in cellular therapy, the undersigned professional organizations believe it is necessary to share the following important message with patients and families contemplating cell therapy or experimental stem cell procedures. In this document, best practices are outlined to assist patients and family members in their healthcare decisions. Controlled innovation in the context of patient safety is paramount as potential therapeutic products or procedures are researched, tested, advanced and proven.
|08/16/2013 - 08:26||
Substances that convert body cells back into stem cells initially activate all genes in the embryo
The Pou5f1 protein acts as an on-switch for embryonic development in zebrafish.
|08/14/2013 - 10:24||
Stanford scientists sequence genome of human's closest invertebrate relative
Botryllus schlosseri, a small sea creature, can regenerate its entire body from its blood vessels alone. Stanford researchers hope that sequencing its genome will lead to advances in regenerative and transplant medicine for humans.
|08/12/2013 - 15:25||
Gamers to join ash dieback fight-back
Let scientists keep the lab coat, goggles and pipette. Playing a Facebook game as simple as Candy Crush is enough to take part in active research to help save the ash tree.
|John Innes Centre|
|08/12/2013 - 08:33||
Tumour suppressor is needed for stem cells to mature into neurons
PRESS RELEASE 12 August 2013] The previously proposed tumour suppressor CHD5 is essential for making nervous system stem cells mature into neurons, according to a new study from Karolinska Institutet. The finding, which is published in the journal Developmental Cell, provides valuable information about how neurons mature and shows why the loss of CHD5 can make tumours of the nerve system more malignant.
|08/11/2013 - 23:53||
Strategy turns molecules in human lung cells into viral scissors that cut H5N1 bird flu and similar bugs into pieces
August 11, 2013 /Press Release/ –– A new strategy that dismantles a viral genome in human lung cells will ensure safe research on deadly strains of influenza, say researchers from the Icahn School of Medicine at Mount Sinai.
|08/08/2013 - 02:16||
Chief Operating Officer of the Multiple Myeloma Research Foundation (MMRF), Walter Capone, Named to the 2013 Pharmavoice 100
The Multiple Myeloma Research Foundation (MMRF) is proud to announce that Walter M. Capone, MMRF Chief Operating Officer, has been selected for the 2013 PharmaVOICE 100. This annual award recognizes top industry leaders for their positive contributions across sectors such as pharmaceutical, biotechnology, contract research, clinical trial, research and development, patient education, advocacy and more. Kathy Giusti, Founder and CEO of the MMRF, was named to the PharmaVOICE 100 in 2009.
|08/07/2013 - 02:45||
Israel's First Biodesign Program Produces Four Startups After One Year
As health costs spiraled over the last decade, the need for more cost-effective health care systems has become increasingly urgent. Medical innovation plays a vital role in making medicine both efficient and affordable — not to mention improving the quality of patient care and ensuring positive outcomes. However, the process of creating new medical devices requires an in-depth understanding of multiple disciplines including medicine, engineering, and finance that few could master alone.
|08/05/2013 - 23:08||
AstraZeneca and FibroGen collaborate to develop and commercialise FG-4592, a treatment for anaemia in chronic kidney disease and end-stage renal disease
AstraZeneca and FibroGen today announced that they have entered into a strategic collaboration to develop and commercialise FG-4592, a first-in-class oral compound in late stage development for the treatment of anaemia associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD).
|08/05/2013 - 08:27||
Simple moss plants outperform us by gene number
At the genetic level, mosses are more complex than humans: A group of German, Belgian and Japanese scientists, coordinated by Professor Ralf Reski from the University of Freiburg, Germany, published a new study where they describe 32,275 protein-encoding genes from the moss Physcomitrella patens. This is about 10,000 genes more than the human genome contains. Mosses are tiny plants with a simple body plan: They have no roots, no flowers and do not produce seeds.
|08/05/2013 - 02:42||
Academy Award-winner Morgan Freeman was honored last night with the Jake Eberts Key of Knowledge Award at a gala reception hosted by
Canadian Friends of the Hebrew University of Jerusalem (CFHU). The award celebrates Freeman's dedication to combating racism and promoting knowledge and education worldwide. The gala was held at the Toronto Centre for the Arts and was attended by more than 700 guests.
|08/01/2013 - 06:09||
HEMACORD ®, the First FDA Licensed Stem Cell Product, Nominated for Prix Galien USA "Best Biotechnology Product" Award
August 1, 2013, New York, NY – The New York Blood Center’s Milstein Cord Blood Program is proud to acknowledge the nomination of its first-in-class hematopoietic stem cell product, HEMACORD® (HPC, Cord Blood) for the 2013 “Best Biotechnology Product” Award by Prix Galien USA. The award, which will be presented at a ceremony October 22 in New York, will recognize “biomedical products that advance the human condition and which were approved by the U.S. Food and Drug Administration (FDA) during the past five years,” according to the Galien Foundation. HEMACORD® is among 13 biotech products nominated for this award.
|New York Blood ...|
|07/31/2013 - 04:31||
University President Joel Seligman Joins Other University Leaders Calling on President Obama, Congress to Restore Investments in Research and Education
The Laboratory for Laser Energetics of the University of Rochester is a national resource for research and education in science and technology.
|07/31/2013 - 01:47||
The University can now support its spin-outs better and for much longer than we could before
The University seed funds, which support new companies based on Cambridge research, saw their biggest-ever return this year, according to annual results from Cambridge Enterprise, the University’s commercialisation arm.
|University of C...|
|07/25/2013 - 04:41||
Stem Cell Agency’s Board Approves $70 Million Plan to Develop Innovative Alpha Clinics
San Francisco, CA – A $70 million plan to create a new statewide network of sites that will act as a hub for stem cell clinical trials was approved by the governing Board of California’s stem cell agency, the California Institute for Regenerative Medicine (CIRM).
|07/25/2013 - 03:06||
Project Engaging High-school Students in Research on Smoking Behavior Wins Science Magazine’s Inquiry-based Instruction Prize
High school students display a poster that presents the results of their database research.
|07/24/2013 - 10:06||
In the not too distant future, your favorite French wine may not come from its namesake region or even from France!
Climate change is altering growing conditions in wine producing regions and in coming decades will change the wines produced there, in some cases shifting to new areas the growth of grape varieties long associated with regions further south, says leading climate scientist and wine expert Antonio Busalacchi (pictured right) of the University of Maryland.
|06/25/2013 - 04:34||
PAREXEL International Announces $100 Million Private Placement
Boston, MA, June 25, 2013 – PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, announced today that the Company has entered into a note purchase agreement with a select group of institutional investors for a private placement financing. Upon completing the transaction, PAREXEL will receive gross proceeds of $100 million from the sale of the notes with a seven year bullet maturity and a 3.11 % coupon.